Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the six-month period from November 1, 2016, to April 30, 2017. The report details the status of various share option and savings-related schemes under the UK Listing Rules (Block Listing Six Monthly Return). The filing was submitted on May 12, 2017.
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The document focuses exclusively on the movement of unallotted securities within specific employee share schemes.
Share Scheme Activity Summary
| Scheme Name | Opening Balance | Issued/Allotted | Ending Balance |
|---|---|---|---|
| GlaxoSmithKline Share Option Plan - Ordinary Shares | 3,530,802 | 1,569,653 | 4,104,101 |
| GlaxoSmithKline Share Option Plan - ADS | 9,349,738 | 553,924 | 8,795,814 |
| GlaxoSmithKline Share Save Plan 2012 | 239,107 | 603,782 | 1,635,325 |
| GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan | 0 | 399,929 | 200,071 |
| GlaxoSmithKline Savings Related Share Option Scheme | 2,742,626 | 0 | 2,742,626 (Lapsed) |
Note: Several legacy schemes (Glaxo Wellcome UK/International, SmithKline Beecham 1989 plans) reported zero activity with no changes to their unallotted balances.
Material Changes
- Ordinary Shares Plan: The balance of unallotted securities increased to 4,104,101 despite 1,569,653 shares being issued. This was due to a net increase of 2,142,952 shares applied for during the period, which included an adjustment of +142,952 shares transferred from the 2009 Deferred Annual Bonus Plan.
- Share Save Plan 2012: The unallotted balance increased significantly to 1,635,325 following an increase of 2,000,000 shares, partially offset by 603,782 shares issued.
- Deferred Bonus Plan: A new balance of 200,071 unallotted shares was established after an increase of 600,000 shares and the issuance of 399,929 shares.
- Expired Scheme: The GlaxoSmithKline Savings Related Share Option Scheme has expired, and the remaining balance of 2,742,626 unallotted shares has lapsed.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, or specific risk factors. The document is a regulatory compliance report regarding share scheme administration.
Investor Verification Checklist
- Verify the impact of the 2,142,952 share increase in the Ordinary Shares Plan on potential future dilution.
- Confirm the treatment of the 2,742,626 lapsed shares from the expired Savings Related Share Option Scheme.
- Review the adjustment of 142,952 shares between the Ordinary Shares Plan and the 2009 Deferred Annual Bonus Plan to ensure accurate accounting of total equity awards.
- Check subsequent filings for the utilization of the 1,635,325 unallotted shares in the Share Save Plan 2012.